P73, P63 and mutant P53: Members of protein complexs floating in cancer cells

Olimpia Monti, Alexander Damalas, Sabrina Strano, Giovanni Blandino

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Approximately half of human tumors bear p53 mutations (Hollestein et al., 1997). The most prevalent type consists of missense mutations that are frequently accompanied by loss of the remaining wild-type p53 (wt-p53) allele (Hainaut et al., 1997; Levine, 1997). The major site of the p53 mutations is the highly conserved DNA binding core domain (Hussain et al., 1998; Prives et al., 1999). Thus, mutant p53 (mt-p53) proteins are unable to specifically bind DNA and to activate specific wt-p53 target genes. Unlike wt-p53, whose half-life is short, mutant p53 proteins are quite stable and abundantly present in cancer cells. One certain outcome of p53 mutations is the loss of wild type activities such as growth arrest, apoptosis, and differentiation (Michalovitz et al., 1990; Yonish-Rouach et al., 1991; Soddu et al., 1996; Almog et al., 1997). However, at variance with other tumor suppressor genes, cells with p53 mutations maintain expression of the fulllength protein. This may suggest that, at least certain mutant forms of p53 can gain additional functions through which actively contribute to cancer progression (Prives et al., 1999; Sigal et al., 2000; Strano et al., 2001; Bullock et al., 2001). Such evidence is provided by several in vitro and in vivo studies (Haley et al., 1990; Dittmer et al., 1993; Gualberto et al., 1998; Frazier et al., 1998; Li et al., 1998; Blandino et al., 1999; Aas et al., 1996; Irwin et al., 2003; Strano et al., 2003).

Original languageEnglish
Title of host publication25 Years of p53 Research
PublisherSpringer Netherlands
Pages223-232
Number of pages10
ISBN (Print)9781402029226, 9781402029202
DOIs
Publication statusPublished - 2005

Fingerprint

Mutation
Mutant Proteins
Neoplasms
Proteins
DNA
p53 Genes
Missense Mutation
Tumor Suppressor Genes
Half-Life
Alleles
Apoptosis
Growth
In Vitro Techniques

ASJC Scopus subject areas

  • Medicine(all)

Cite this

P73, P63 and mutant P53 : Members of protein complexs floating in cancer cells. / Monti, Olimpia; Damalas, Alexander; Strano, Sabrina; Blandino, Giovanni.

25 Years of p53 Research. Springer Netherlands, 2005. p. 223-232.

Research output: Chapter in Book/Report/Conference proceedingChapter

Monti, Olimpia ; Damalas, Alexander ; Strano, Sabrina ; Blandino, Giovanni. / P73, P63 and mutant P53 : Members of protein complexs floating in cancer cells. 25 Years of p53 Research. Springer Netherlands, 2005. pp. 223-232
@inbook{d62801a51180499983d129cffe6507c5,
title = "P73, P63 and mutant P53: Members of protein complexs floating in cancer cells",
abstract = "Approximately half of human tumors bear p53 mutations (Hollestein et al., 1997). The most prevalent type consists of missense mutations that are frequently accompanied by loss of the remaining wild-type p53 (wt-p53) allele (Hainaut et al., 1997; Levine, 1997). The major site of the p53 mutations is the highly conserved DNA binding core domain (Hussain et al., 1998; Prives et al., 1999). Thus, mutant p53 (mt-p53) proteins are unable to specifically bind DNA and to activate specific wt-p53 target genes. Unlike wt-p53, whose half-life is short, mutant p53 proteins are quite stable and abundantly present in cancer cells. One certain outcome of p53 mutations is the loss of wild type activities such as growth arrest, apoptosis, and differentiation (Michalovitz et al., 1990; Yonish-Rouach et al., 1991; Soddu et al., 1996; Almog et al., 1997). However, at variance with other tumor suppressor genes, cells with p53 mutations maintain expression of the fulllength protein. This may suggest that, at least certain mutant forms of p53 can gain additional functions through which actively contribute to cancer progression (Prives et al., 1999; Sigal et al., 2000; Strano et al., 2001; Bullock et al., 2001). Such evidence is provided by several in vitro and in vivo studies (Haley et al., 1990; Dittmer et al., 1993; Gualberto et al., 1998; Frazier et al., 1998; Li et al., 1998; Blandino et al., 1999; Aas et al., 1996; Irwin et al., 2003; Strano et al., 2003).",
author = "Olimpia Monti and Alexander Damalas and Sabrina Strano and Giovanni Blandino",
year = "2005",
doi = "10.1007/978-1-4020-2922-6_10",
language = "English",
isbn = "9781402029226",
pages = "223--232",
booktitle = "25 Years of p53 Research",
publisher = "Springer Netherlands",

}

TY - CHAP

T1 - P73, P63 and mutant P53

T2 - Members of protein complexs floating in cancer cells

AU - Monti, Olimpia

AU - Damalas, Alexander

AU - Strano, Sabrina

AU - Blandino, Giovanni

PY - 2005

Y1 - 2005

N2 - Approximately half of human tumors bear p53 mutations (Hollestein et al., 1997). The most prevalent type consists of missense mutations that are frequently accompanied by loss of the remaining wild-type p53 (wt-p53) allele (Hainaut et al., 1997; Levine, 1997). The major site of the p53 mutations is the highly conserved DNA binding core domain (Hussain et al., 1998; Prives et al., 1999). Thus, mutant p53 (mt-p53) proteins are unable to specifically bind DNA and to activate specific wt-p53 target genes. Unlike wt-p53, whose half-life is short, mutant p53 proteins are quite stable and abundantly present in cancer cells. One certain outcome of p53 mutations is the loss of wild type activities such as growth arrest, apoptosis, and differentiation (Michalovitz et al., 1990; Yonish-Rouach et al., 1991; Soddu et al., 1996; Almog et al., 1997). However, at variance with other tumor suppressor genes, cells with p53 mutations maintain expression of the fulllength protein. This may suggest that, at least certain mutant forms of p53 can gain additional functions through which actively contribute to cancer progression (Prives et al., 1999; Sigal et al., 2000; Strano et al., 2001; Bullock et al., 2001). Such evidence is provided by several in vitro and in vivo studies (Haley et al., 1990; Dittmer et al., 1993; Gualberto et al., 1998; Frazier et al., 1998; Li et al., 1998; Blandino et al., 1999; Aas et al., 1996; Irwin et al., 2003; Strano et al., 2003).

AB - Approximately half of human tumors bear p53 mutations (Hollestein et al., 1997). The most prevalent type consists of missense mutations that are frequently accompanied by loss of the remaining wild-type p53 (wt-p53) allele (Hainaut et al., 1997; Levine, 1997). The major site of the p53 mutations is the highly conserved DNA binding core domain (Hussain et al., 1998; Prives et al., 1999). Thus, mutant p53 (mt-p53) proteins are unable to specifically bind DNA and to activate specific wt-p53 target genes. Unlike wt-p53, whose half-life is short, mutant p53 proteins are quite stable and abundantly present in cancer cells. One certain outcome of p53 mutations is the loss of wild type activities such as growth arrest, apoptosis, and differentiation (Michalovitz et al., 1990; Yonish-Rouach et al., 1991; Soddu et al., 1996; Almog et al., 1997). However, at variance with other tumor suppressor genes, cells with p53 mutations maintain expression of the fulllength protein. This may suggest that, at least certain mutant forms of p53 can gain additional functions through which actively contribute to cancer progression (Prives et al., 1999; Sigal et al., 2000; Strano et al., 2001; Bullock et al., 2001). Such evidence is provided by several in vitro and in vivo studies (Haley et al., 1990; Dittmer et al., 1993; Gualberto et al., 1998; Frazier et al., 1998; Li et al., 1998; Blandino et al., 1999; Aas et al., 1996; Irwin et al., 2003; Strano et al., 2003).

UR - http://www.scopus.com/inward/record.url?scp=33646802302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646802302&partnerID=8YFLogxK

U2 - 10.1007/978-1-4020-2922-6_10

DO - 10.1007/978-1-4020-2922-6_10

M3 - Chapter

AN - SCOPUS:33646802302

SN - 9781402029226

SN - 9781402029202

SP - 223

EP - 232

BT - 25 Years of p53 Research

PB - Springer Netherlands

ER -